Milad Alucozai

Milad Alucozai is a prominent professional in the biotechnology and healthcare sectors, currently serving as Co-Founder and Board Member at Revalia Bio, where AI-powered digital twins of human organs are being developed for biomedical research. Additionally, Alucozai co-hosts the Code to Cure series at the Wyss Institute at Harvard University, focusing on the intersection of AI, biology, and healthcare. As a first investor and Board Member at Seqera Labs, Alucozai supports scientific data analysis for modern biotech applications. Other roles include Strategic Expert in Residence at Digitalis Commons for ARPA-H, Board Member at Talus Bio, and Senior Advisor at 16 Tech Innovation District. With a strong educational background from institutions such as Harvard University and Purdue University, Alucozai has significantly contributed to various entrepreneurial ventures, including a notable tenure as Head of Life Sciences & Deep Tech at BoxOne Ventures. Recognized for exceptional mentorship, Alucozai received the Mentor of the Year Award from the Creative Destruction Lab.